PO.TB10.06 · 肿瘤生物学
使用BD®OMICS-One-Protein-Panels进行CITE-seq对肺肿瘤微环境的整合转录组学和蛋白质组学表征
Integrated transcriptomic and proteomic characterization of the lung tumor microenvironment using BD®OMICS-One-Protein-Panels for CITE-seq
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
肿瘤微环境(TME)是一个异质且持续演化的系统。它由恶性细胞、大量浸润性免疫细胞、间质细胞、血管和细胞外基质组成。肿瘤细胞与非肿瘤细胞的相互作用产生免疫反应性环境,改变细胞表型和功能,从而促进肿瘤生长和进展或抗肿瘤免疫。以高分辨率刻画TME的组成及改变,对于识别影响癌症进展的因素或评估免疫治疗疗效至关重要。单细胞多组学技术的进步为以高分辨率审视肿瘤和TME提供了强大手段,揭示了离散的细胞亚群及其潜在功能。通过测序进行的转录组和表位细胞索引(CITE-seq)利用寡核苷酸标记抗体,实现了单细胞RNA测序与表面蛋白图谱分析的同时进行。通过结合来自同一细胞的蛋白质组和转录组数据,CITE-seq是对离散细胞群进行表型分析的一种尤为强大的方法,特别适用于TME。
在此,我们将CITE-seq应用于临床相关的人类肺癌样本。使用BD Horizon™ Dri肿瘤和组织解离试剂获得单细胞悬液,然后用BD®OG-冻存缓冲液(一种非交联缓冲液)冻存。在另一地点,使用BD OMICS-One™ WTA Next检测以及BD®OMICS-One-Protein-Panels(冻干且预滴定的寡核苷酸标记抗体面板)对样本进行CITE-seq。转录组和蛋白质组数据的非监督聚类揭示了12个主要细胞簇,包括浸润性淋巴细胞(TILs)、驻留和浸润性免疫细胞,以及非免疫的肿瘤内在细胞。检测到50余个蛋白表位,用于通过非小细胞肺癌已充分发表的蛋白特征表达来识别肿瘤内在细胞。差异基因和蛋白表达谱区分了不同的组织驻留肺泡巨噬细胞与浸润性血源性巨噬细胞。此外,利用初始(naive)、激活/刺激和耗竭状态的T细胞基因集来识别TILs的功能异质性。我们在该样本中成功检测到五十余个表位,当与转录组数据整合时,能够识别癌症特异性细胞状态、多样的免疫功能以及与其他细胞的潜在相互作用。我们展示了从样本采集、储存、单细胞捕获、测序到分析的端到端工作流程,以表征TME异质性并进一步理解肿瘤生物学。
不用于诊断或治疗程序。©2025 BD。保留所有权利。
查看英文原文 English abstract
The tumor microenvironment (TME) is a heterogeneous and continuously evolving system. It is composed of malignant cells, numerous infiltrating immune cells, stromal cells, blood vessels, and extracellular matrix. The interactions of tumor and non-tumor cells produce an immune-reactive milieu, altering cellular phenotypes and function, thus contributing to tumor growth and progression or antitumor immunity. Profiling the components and alterations in the TME at high resolution is crucial to identify factors influencing cancer progression or evaluating the efficacy of immunotherapies. Advancements of single cell multiomics techniques provide powerful means to scrutinize the tumor and TME at high resolution, shedding light on discrete cell subsets and their potential functions. Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq) enables concurrent single-cell RNA sequencing alongside surface protein profiling by using oligonucleotide-tagged antibodies. By combining proteomic and transcriptomic data from the same cell, CITE-seq is an especially powerful approach for phenotyping discrete cell populations, especially suitable for the TME.
Here we applied CITE-seq to clinically relevant human lung cancer samples. A single cel suspension was obtained with BD Horizon™ Dri Tumor & Tissue Dissociation Reagent and then frozen with BD®OG-Cryopreservation Buffer, a non-cross-linking buffer. At another location, CITE-seq was conducted on the samples with the BD OMICS-One™ WTA Next Assay as well as the BD®OMICS-One-Protein-Panels, which are lyophilized and pre-titrated oligonucleotide-tagged antibody panels. Non-supervised clustering of transcriptomic and proteomic data revealed 12 major cell clusters, including infiltrating lymphocytes (TILs), resident and infiltrating immune cells, as well as non-immune intrinsic tumor cells. Over 50 protein epitopes were detected and used to identify tumor intrinsic cells with their expression of well published protein signatures of non-small cell lung cancer. Differential gene and protein expression profiles distinguish distinct tissue-resident alveolar-macrophages from infiltrating hematogenous macrophages. Moreover, T cell gene sets of naive, activation/stimulation, and exhaustion states were used to identify the functional heterogeneity of TILs. We successfully detected over fifty epitopes in this sample, enabling the identification of cancer specific cellular states, varied immune functions and potential interactions with other cells, when integrated with transcriptomic data. We demonstrate an end-to-end workflow from sample collection, storage, single-cell capture, sequencing, and analysis to characterize TME heterogeneity and further understand tumor biology.
Not for use in diagnostic or therapeutic procedures.©2025 BD. All rights reserved.
利益披露 Disclosure
S. X. Shi, None..
C. Sakofsky, None..
H. Song, None..
M. Thakran, None..
T. Kobayashi, None..
A. Ayer, None.